BI 3000202 clinical trials
Also written BI 3000202.
How each study uses BI 3000202 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BI 3000202 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 3000202
- 7
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BI 3000202.
- Feb 2027A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver ProblemsPhase 1 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses BI 3000202 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)RecruitingPhase 2Boehringer IngelheimNCT07409181Written as BI 3000202
- A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver ProblemsRecruitingPhase 1Boehringer IngelheimNCT07486102Written as BI 3000202
- A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodActive, not recruitingPhase 1Boehringer IngelheimNCT07774325Written as BI 3000202
- A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the BloodCompletedPhase 1Boehringer IngelheimNCT05945888Written as BI 3000202
- A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT07273474Written as BI 3000202
- A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT07215260Written as BI 3000202
- A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles MidazolamCompletedPhase 1Boehringer IngelheimNCT06327256Written as BI 3000202